| Name | Title | Contact Details |
|---|
At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN
Auconet was founded in 1998 by a German engineering team with deep expertise in IT Operations Management. Originally, a systems integrator, engaged by Global 1000 enterprises to monitor, manage, and maintain vast enterprise networks, using existing platforms, Auconet recognized the need for a better approach. Auconet`s customers had been unable to find any truly vendor-independent solution for network management. Instead, customers were locked into proprietary network management solutions that each hardware vendor offered to monitor, manage, control, and secure their own devices. The resulting vendor lock-in created unacceptable risk, cost, and inconvenience. Auconet`s Global 1000 customers were looking for a better approach. Auconet studied its customers` challenges in depth, and developed the Auconet Business Infrastructure Control Solution (BICS). BICS not only provides network infrastructure management for all vendors` devices and endpoints, but also serves as the foundation for a new generation of IT infrastructure management.
Analytical Design Service is a Ann Arbor, MI-based company in the Business Services sector.
Delta and Pine Land Co. is a Germantown, TN-based company in the Business Services sector.
Courtyard Travel is a Great Neck, NY-based company in the Business Services sector.